Biotechnology News and Research

RSS

Genzyme provides update on discussions with Sanofi-Aventis

Genzyme Corp. (NASDAQ: GENZ) reported today that discussions between its financial advisors and financial advisors for Sanofi-Aventis are continuing and have expanded to include representatives of both companies.

11 Jan 2011

PDL disagrees with certain aspects of court's decisions on litigation with MedImmune

PDL BioPharma, Inc. today announced that on January 7, 2011, the United States District Court for the Northern District of California issued summary judgment order deciding certain issues favorably and other issues adversely to PDL in its litigation with MedImmune. PDL disagrees with certain aspects of the court's decisions which are adverse to the Company and is evaluating its legal options, including appeal of these decisions.

11 Jan 2011

BiAqua, DSM enter partnership for strain and process development of BiAqua Ferritin

DSM BioSolutions, Royal DSM's microbial fermentation contract manufacturing business, and BiAqua B.V., an innovator in delivering bio-based solutions for serious water contamination issues, today announced that they have entered into an agreement for strain development, process development and production of "BiAqua Ferritin" for BiAqua's core technology to address bio-fouling and arsenic contamination in the water sector.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant, is providing an update regarding its efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.

11 Jan 2011

New insights into estrogen receptor beta

Research with significant implications in the treatment and intervention of cancer and obesity has been published recently in two prestigious journals by University of Houston (UH) biochemist Dr. Jan--ke Gustafsson.

11 Jan 2011

PPD announces joint venture with TBL to develop novel biotherapeutics

PPD, today announced it has established a joint venture with Taijitu Biologics Limited in the area of the discovery of novel biotherapeutics. The joint venture, named BioDuro Biologics, expands PPD's capability to deliver unique, highly differentiated drug discovery services for biopharmaceutical companies across the globe.

10 Jan 2011

PharPoint Research joins Medidata's ASPire to Win channel partner program

Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.

10 Jan 2011

Genetics Squared to change corporate name to Everist Genomics

Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Genomics and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.

10 Jan 2011

CoreLab Partners releases ImagEngine imaging sciences application

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm, Inc and Medifacts International, has launched a new advanced imaging application named ImagEngine®.

10 Jan 2011

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Advanced Pain Remedies, a subsidiary of Cato BioVentures, announces that a three million dollar grant has been received, to advance its lead development candidate, SP-SAP. Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases, has been awarded a $3 million grant from the National Cancer Institute (NCI).

10 Jan 2011

T2 Biosystems relocates to new 20,000 sq.ft. facility in Lexington

T2 Biosystems, Inc., a company developing next-generation medical diagnostic products, today announced that it has relocated to a newly renovated 20,000 sq.ft. facility located in Lexington, MA.

10 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Civitas receives $20 million Series A financing

Civitas Therapeutics, Inc., a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies, announced today that it has secured a $20 million Series A financing from founding investor, Longitude Capital, along with co-lead Canaan Partners. The proceeds of the financing will be primarily used to advance Civitas' lead program for treating patients with Parkinson's disease through clinical proof-of-concept.

10 Jan 2011

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin(R) scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts around a predetermined Takeda target.

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

U.S. District Court grants injunction for Sensipar patents

A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's Sensipar® (cinacalcet) until expiration of the drug's U.S. patents.

10 Jan 2011

Scientists discover new anti-cancer mechanism

Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG prevents metastasis of tumor cells and enhances chemotherapy efficiency.

10 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Biotechnology News and Research

Genzyme provides update on discussions with Sanofi-Aventis

PDL disagrees with certain aspects of court's decisions on litigation with MedImmune

BiAqua, DSM enter partnership for strain and process development of BiAqua Ferritin

QIAGEN to acquire minority stake in Alacris Theranostics

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

New insights into estrogen receptor beta

PPD announces joint venture with TBL to develop novel biotherapeutics

PharPoint Research joins Medidata's ASPire to Win channel partner program

Genetics Squared to change corporate name to Everist Genomics

CoreLab Partners releases ImagEngine imaging sciences application

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

T2 Biosystems relocates to new 20,000 sq.ft. facility in Lexington

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Civitas receives $20 million Series A financing

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

U.S. District Court grants injunction for Sensipar patents

Scientists discover new anti-cancer mechanism

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News